Allos' drug has always been a long shot, but there has been some hope for Genasense.
FORBES: Biotech's Big Losers
One worry among some analysts is that bad news for Genasense and Allos will push all biotech stocks down.
Investors have already voted: both Genta and Allos Therapeutics got 40%-plus haircuts today, making them the top two percentage losers on the Nasdaq.
Behind the stock drops are briefing documents from FDA staff that called data supporting Genta's Genasense and Allos' RSR13 unconvincing at best.
It is in the process of completing the acquisition of Allos Therapeutics (ALTH), whose drug, Folotyn, is a small-molecule therapeutic for cancer.
FORBES: Why This Tiny But Profitable Biotech May Be Gobbled Up By Big Pharma
"We were able to estimate that a minimum of 30 percent and possibly even more than 50 percent of GBS patients had had preceding campylobacter infection, " said Dr. Ban Mishu Allos of Vanderbilt University's School of Medicine.
CNN: Is the government fighting food poisoning?
应用推荐
模块上移
模块下移
不移动